Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?

Molecular portraits of human breast tumours

Charles M. Perou, Thérese Sørlie, Michael B. Eisen et al. · Nature · 2000 · 16.3K citations

Medicine, Molecular Biology, Oncology +14

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations

Medicine, Oncology, Pharmacology +16

A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer

Umberto Veronesi, Giovanni Paganelli, Giuseppe Viale et al. · New England Journal of Medicine · 2003 · 2.2K citations · Full text

Medicine, Oncology, Surgery +15

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

David N. Krag, Stewart Anderson, Thomas B. Julian et al. · The Lancet Oncology · 2010 · 1.9K citations · Full text

Medicine, Oncology, Surgery +17